August 04, 2009
FDA accepts BLA for IV-AAT, a treatment for alpha-1 antitrypsin deficiencyKamada announced that the FDA has accepted for filing the Biologics License Application (BLA) submitted for intravenous alpha-1 antitrypsin (IV-AAT). IV-AAT is being developed for the treatment of alpha-1 antitrypsin deficiency. IV-AAT is a high purity, liquid, ready-to-use human plasma derived AAT, produced by a proprietary chromatographic purification method.
For more information visit www.kamada.com.